Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
Lipid abnormalities in people with the Metabolic Syndrome (the Insulin Resistance Syndrome)
are characterized by elevations in triglycerides and LDL cholesterol; low levels of HDL
cholesterol; and small, dense LDL particles. Statins generally do not change LDL particle
size, so often fenofibrate is added. This combination may still not be sufficient. Niacin is
a common third drug added to the treatment regimen, but niacin can increase insulin
resistance. This study compares niacin as a third drug to rosiglitazone, an insulin
sensitizer.